ABBV Stock: Price, Earnings History and SEC Filings
AbbVie Inc. (ABBV) last traded at $294.89, up 1.41% on the latest session and up 12.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $3.65 against an analyst estimate of $3.64, a beat of 0.3%.
$294.89 +1.41%
1 month+12.73%
52-week high$298.74
52-week low$190.75
Volume6.90M
ExchangeNYSE
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ABBV earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 31, 2026 | $3.65 | $3.64 | +0.27% |
| Mar 2026 | Apr 29, 2026 | $2.65 | $2.62 | +1.15% |
| Dec 2025 | Feb 4, 2026 | $2.71 | $2.66 | +1.88% |
| Sep 2025 | Oct 31, 2025 | $1.86 | $1.77 | +5.08% |
ABBV beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for ABBV
SEC filing data is not available right now. You can search for ABBV on SEC EDGAR.
ABBV news
- 5 Most Undervalued Dividend Growth Stocks According to Hedge FundsNov 1, 2026 · finance.yahoo.com
- AbbVie Stock Hits a Record After a 5.2% Dividend Raise: Why Its 276% Payout Ratio Doesn’t Tell the Entire StoryNov 1, 2026 · tikr.com
- AbbVie: 3 Key Takeaways for Long-Term InvestorsOct 31, 2026 · fool.com
- Is AbbVie a Buy After Its Latest Earnings Report?Oct 31, 2026 · fool.com
- Is Earnings Beat Altering The Investment Case For AbbVie Stock (ABBV)?Oct 31, 2026 · finance.yahoo.com
- AbbVie (ABBV) Q3 2026 Earnings Call TranscriptOct 30, 2026 · fool.com
- AbbVie's Earnings Double As Immunology Powerhouse Skyrizi Beats AgainOct 30, 2026 · finance.yahoo.com
- Q3 earnings round-up: AstraZeneca, AbbVie, KenvueOct 30, 2026 · finance.yahoo.com
About AbbVie Inc.
AbbVie Inc. (ABBV) is a US-listed public company on NYSE.